Influenza – Production of a live attenuated influenza virus vaccine
With a novel method it is possible for the first time to produce a live attenuated influenza A virus vaccine. The method is based on the production of specific mutants of influenza viruses which in vivo are in fact immunogenic, but not pathogenic. Their genome largely corresponds with that of the currently active epidemic strain, allowing their utilisation as attenuated recombinant vaccine against the influenza virus. Due to the particular characteristics of the influenza virus mutants, the application of this vaccine will be possible for children, elderly people and even immunodeficient people.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
